Last reviewed · How we verify
Prostanoids
At a glance
| Generic name | Prostanoids |
|---|---|
| Sponsor | Seoul National University Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- A Phase 2, Single-masked, Randomized, Crossover Study Of The 24-hour Intraocular Pressure Lowering And Systemic Exposure of Pf-04217329 Alone And In Combination With Latanoprost (Phase 2)
- Novel Endpoints in Cough Challenge Testing. (N/A)
- Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker (Phase 4)
- Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH) (N/A)
- TrEatment Approach in the Multimodal Era Registry (N/A)
- The in Vivo Effect of Medical and Surgical Glaucoma Treatments on the Schlemm's Canal (NA)
- NCT01317862 (NA)
- Efficacy and Safety of Prostaglandin Analogue and Carbonic Anhydrase Inhibitor for the Treatment of Pediatric Glaucoma (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prostanoids CI brief — competitive landscape report
- Prostanoids updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI